Form 4: OPKO Health CEO Frost Boosts Stake with 580,000 Share Purchase

Phillip Frost, CEO and Chairman of OPKO Health, reported the acquisition of 580,000 shares of common stock through indirect holdings on November 21, 2025.

Summary

• Phillip Frost, MD, CEO and Chairman of OPKO Health, along with Frost Gamma Investments Trust, reported multiple purchases of OPKO Health common stock.
• A total of 580,000 shares were acquired on November 21, 2025, through various transactions.
• The purchase prices for these shares ranged from $1.30 to $1.335 per share.
• Following these transactions, the indirect beneficial ownership through Frost Gamma Investments Trust increased to 216,706,448 shares.
• Phillip Frost also directly owns 3,568,951 shares and indirectly owns 30,127,177 shares through Frost Nevada Investments Trust.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.
• The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.

Sentiment

Score: 8

Explanation: The significant insider buying by the CEO and Chairman, Phillip Frost, through a Rule 10b5-1 plan, indicates a structured and sustained confidence in the company's future prospects and valuation. This is a very positive signal for investors, demonstrating management's belief in the company's long-term value.

Positives

• Significant insider buying by the CEO and Chairman, Phillip Frost, indicating confidence in the company's future.
• Acquisition of 580,000 shares of common stock.
• The purchases were made at prices ranging from $1.30 to $1.335 per share, demonstrating a specific valuation point for the insider.

Future Outlook

The filing indicates transactions made pursuant to a Rule 10b5-1(c) plan, which allows insiders to establish pre-arranged plans for buying or selling securities. The establishment of such a plan for purchases by the CEO and Chairman can be interpreted as a structured expression of confidence in the company's long-term value.

Management Comments

• Phillip Frost, M.D., as Trustee, signed the filing.
• The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein.

Industry Context

Insider buying, especially by a CEO and Chairman, is often viewed positively by the market as it signals management's belief in the company's intrinsic value and future prospects, potentially outperforming peers or broader market trends. Transactions made under a 10b5-1 plan suggest a pre-meditated investment strategy rather than a reaction to immediate market conditions.

Stakeholder Impact

• Shareholders may view the significant insider buying as a positive indicator of management's confidence, potentially leading to increased investor interest and share price stability or appreciation.

Next Steps

• The filing does not specify future actions or milestones, as it is a report of completed insider transactions.

Key Dates

Recommendation

The substantial purchase of 580,000 shares by CEO and Chairman Phillip Frost, at prices ranging from $1.30 to $1.335, signals strong conviction in OPKO Health's current valuation and future growth prospects. Such significant insider buying by a key executive, especially when executed under a Rule 10b5-1 plan, is often interpreted by seasoned investors as a bullish indicator, suggesting the stock may be undervalued or poised for positive developments.

Keywords

OPKO Health, OPK, Phillip Frost, Insider Buying, Stock Purchase, CEO, Chairman, Form 4, Beneficial Ownership, Equity Acquisition, 10b5-1 Plan